Tip: Access positions for across all investors

Analyze quarterly positions in Therapeutics Acquisition Cor with up to 7 years of data, all consolidated into one spreadsheet

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Top investors of Therapeutics Acquisition Cor stock

Who bought or sold THERAPEUTICS ACQUISITION COR this quarter?

Fund or Company Name Shares Held Valued At Change in Shares As Of
Perceptive Advisors 1.5M $16M 0% Mar 2021
BlackRock 1.5M $16M 0% Mar 2021
Suvretta Capital Management 1.1M $11M 100% Mar 2021
venBio Select Advisor 1.0M $11M 0% Mar 2021
Franklin Resources 1.0M $11M 0% Mar 2021
Bain Capital Life Sciences Investors 1.0M $11M 0% Mar 2021
Sphera Funds Management 720k $7.6M 3500% Mar 2021
Citadel Advisors 509k $5.4M 2% Mar 2021
Rtw Investments 490k $5.1M 0% Mar 2021
Point72 Asset Management 375k $3.9M 100% Mar 2021
Foresite Capital Management IV 350k $3.7M 0% Mar 2021

Setup an alert

Want to be notified whenever an investor makes a significant change to their holdings of Therapeutics Acquisition Cor?

Foresite Capital Management V 350k $3.7M 0% Mar 2021
Wellington Management Company 348k $3.7M -60% Mar 2021
Weiss Asset Management LP[1 259k $2.7M 100% Mar 2021
J. Goldman & Co 170k $1.8M 100% Mar 2021
Henderson Group 97k $1.0M -21% Mar 2021
Fairmount Funds Management 50k $526k 100% Mar 2021
Sigma Planning 21k $225k 87% Mar 2021
Claro Advisors 15k $162k 100% Mar 2021
Magnetar Financial 13k $137k 100% Mar 2021
S.A.C. Capital Advisors 8.2k $87k 100% Mar 2021
UBS Group 4.5k $48k 377% Mar 2021
Tower Research Capital 220.00 $2.0k 100% Mar 2021

Who sold out of Therapeutics Acquisition Cor?

Fund or Company Name Date Sold Shares Held Valued At
T. Rowe Price Associates Dec 2020 922k $13M
TD Asset Management Dec 2020 49k $687k
Monashee Investment Management Dec 2020 47k $658k
Silverarc Capital Management Dec 2020 39k $543k
Wells Fargo & Company Dec 2020 2.0k $28k
Wolverine Asset Management Dec 2020 1.0k $14k